|Bid||86.43 x 1300|
|Ask||89.13 x 800|
|Day's Range||86.76 - 88.22|
|52 Week Range||61.05 - 89.93|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||29.09|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||0.88 (1.00%)|
|1y Target Est||92.60|
Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
The big shareholder groups in Baxter International Inc. (NYSE:BAX) have power over the company. Large companies...
GNC Holdings' (GNC) recent joint venture with vitamins and nutritional supplement manufacturer International Vitamin Corporation shows high prospects at present.
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.
Zimmer Biomet (ZBH) prepares for the commercial launch of improvised knee replacement procedures through its flagship program, Persona Revision Knee System.
Baxter International Inc. (BAX), a leading global medical products company, today entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies. The agreement demonstrates Baxter’s ongoing commitment to improving clinical outcomes with an established patient monitoring technology to better inform and guide clinicians’ treatment decisions.
The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.
Given the lack of an alternative therapy to replace tricuspid regurgitation surgery, Abbott (ABT) should be at an advantage in this space.
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.